ASCO 2024 | Challenges in developing and implementing new therapies for head and neck cancers

Ari Rosenberg, MD, University of Chicago, Chicago, IL, discusses challenges in developing new therapies for head and neck cancers, emphasizing the heterogeneity of HPV-positive and HPV-negative tumors. The need for predictive biomarkers to select suitable patients and the importance of randomized studies for integrating novel therapies into standard treatment are highlighted. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.